

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: K. IIDA, et al.
Serial No.: 10/590,845
Filed: AUGUST 28, 2006
For: PREVENTIVE AND/OR THERAPEUTIC AGENT FOR
NEUTROPHILIC INFLAMMATORY DISEASES
Group AU: 1614
Examiner: Gregg Polansky
Confirm. No.: 1367

RESPONSE

Mail Stop: AMEND – NO FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

April 26, 2010

Sir:

In response to the Office Action mailed March 24, 2010, Applicants respectfully elect the Group I claims, that is, claims 1-61 and 68-76, which the Examiner characterizes as being drawn to compounds of formulas (I)-(III). This election is made without traverse.

Further, in response to the Examiner's requirement to elect a single species of Group I, Applicants respectfully elect Compound 127 (see Table 9 on page 105 of Applicants' Substitute Specification submitted August 28, 2006 (hereinafter Applicants' Substitute Specification)).

It is noted that the Examiner indicates that all claims are generic. See Item 4 on page 4 of the Office Action mailed March 24, 2010. Accordingly, it is respectfully submitted that all of the Group I claims, claims 1-61 and 68-76, read on the elected species.